

X EDIZIONE

Giornate Mediche di Santa Maria Nuova 2018



IL DANNO TISSUTALE ISCHEMICO:

sedi anatomiche, strategie terapeutiche e reti assistenziali

18-19 Ottobre 2018

Sala Verde - Palazzo Incontri - Banca CR Firenze
Via De' Pucci, 1 - Firenze

Lo STEMI: uno stallone domato ?



Tania Chechi

f.f. S.C. Cardiologia Firenze 2

tania.chechi@uslcentro.toscana.it



Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006





Figure 2. In-Hospital and 6-Month Outcomes in Patients With ST-Segment Elevation Myocardial Infarction or Left Bundle-Branch Block




JAMA. 2007;297:1892-1900

The sample size of the ST-segment elevation myocardial infarction cohort varied over time. Percentages are based on eligible patients for respective treatments in each period, shown in Table 3 for the first and last periods. CHF indicates congestive heart failure; MI, myocardial infarction. For in-hospital outcomes, P<.01 for recurrent MI or MI diagnosed 24 hours after presentation to hospital; P=.02 for shock; and P<.001 for death. For 6-month outcomes, P=.01 for MI and P=.04 for stroke.

Conclusions In this multinational observational study, improvements in the management of patients with ACS were associated with significant reductions in the rates of new heart failure and mortality and in rates of stroke and mycoardial infarction at 6 months.


Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014


Karolina Szummer^{1,2}*, Lars Wallentin³, Lars Lindhagen³, Joakim Alfredsson^{4,5}, David Erlinge^{6,7}, Claes Held³, Stefan James³, Thomas Kellerth⁸, Bertil Lindahl³, Annica Ravn-Fischer⁹, Erik Rydberg^{6,7}, Troels Yndigegn^{6,7}, and Tomas Jernberg¹⁰



Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014

Karolina Szummer^{1,2}*, Lars Wallentin³, Lars Lindhagen³, Joakim Alfredsson^{4,5}, David Erlinge^{6,7}, Claes Held³, Stefan James³, Thomas Kellerth⁸, Bertil Lindahl³, Annica Ravn-Fischer⁹, Erik Rydberg^{6,7}, Troels Yndigegn^{6,7}, and Tomas Jernberg¹⁰





Relation between door-to-balloon times and mortality after primary percutaneous coronary intervention over time: a retrospective study

Brahmajee K Nallamothu, Sharon-Lise T Normand, Yongfei Wang, Timothy P Hofer, John E Brush Jr, John C Messenger, Elizabeth H Bradley, John S Rumsfeld, Harlan M Krumholz






Figure 2: Predicted in-hospital and 6-month mortality from the multilevel model over a range of patient-specific D2B times


All other covariates were held constant, including secular trends at the population level.





Interpretation Shorter patient-specific D2B times were consistently associated with lower mortality over time, whereas secular trends suggest increased mortality risk in the growing and changing pPCI population. The absence of association of annual D2B time and changes in mortality at the population level should not be interpreted as an indication of its individual-level relation in patients with STEMI undergoing primary PCI.

Impact of age on the effect of pre-hospital $P2Y_{12}$ receptor inhibition in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: the ATLANTIC-Elderly analysis




ure 3. Key findings of the ATLANTIC-Elderly substudy. CRF: chronic renal failure; PE: primary endpoint; DST: definite stent thrombosis

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

rombotic therapy and secondary prevention treatments.^{6,8,11,12} Still, mortality remains substantial with approximately 12% of patients dead within 6 months, ¹³ but with higher mortality rates in higher-risk patients, ¹⁴ which justifies continuous efforts to improve quality of care, adherence to guidelines and research.



Adherence to secondary prevention therapies in acute coronary syndrome

1 Examples of factors that may reduce adherence to therapy

Patient

- Physical impairment (impaired dexterity, poor vision)
- Cognitive impairment
- Psychological (depression)
- Language barriers (non-English speaking)
- Health literacy
- Comorbidities

Health system

- Poor patient-provider relationship
- Health professionals' lack of time and lack of incentives
- Poor continuity of care (hospital-community care transition)
- Geographic location and access to services, pharmacies and transport

Therapy

- Complex regimen (multiple dosing during the day)
- Complex dose (frequent titrations or substitution)
- Polypharmacy
- Side effects

Socioeconomic

- Income
- Low levels of patient education and/or literacy
- Poor social support (single status)
- Unstable living conditions (homeless, frequent travel, shift workers)

5 SII	5 SIMPLE approach to enhance adherence ³⁶					
S	Simplify the regimen	 Adjust timing, frequency and number of tablets to suit patient Attempt to change the situation, not the patient Encourage use of adherence aids (eg, mobile appreminders) 				
1	Impart knowledge	 Focus on patient-provider shared decision making Provide written and verbal instructions Simple language and 3-4 major points Encourage involvement of nurse and pharmacist 				
М	Modify patient beliefs and human behaviour	 Empower patient to self-manage the condition Ensure patient understands the risk of not taking the medication Address fears and concerns of patient 				
Р	Provide communication and trust	 Clear communication from provider Build safe environment where patient feels comfortable Informed and shared decision making 				
L	Leave bias	 Self-learning exercise in area and incorporating into practice Use of culturally and linguistically appropriate interventions Tailor education to patient's level of understanding 				
Е	Evaluate adherence	 Periodic review Self-report and medication adherence scales Biochemical tests — definitive confirmation 				

Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome



Opportunities for Improvement

Benjamin J. Hirsh, MD,* Nathaniel R. Smilowitz, MD,† Robert S. Rosenson, MD,* Valentin Fuster, MD, PhD,* Laurence S. Sperling, MD‡

First Author (Ref. #)	Registry	Years	N	Statin Adherence	Inclusion Criteria	Follow-Up (Yrs)
Ho et al. (51)	PREMIER	2003-2004	2,498	78.5%*	Adults hospitalized with ACS, discharged alive, no contraindications to statin	1
Ho et al. (32)	KPCO	2000-2005	13,596	74%†	Patients in Kaiser CAD registry with prior MI, PCI, or CABG	4.1
Muntner et al. (23)	CMS Chronic Condition Data Warehouse	2007-2009	2,695	63.8%‡	Medicare beneficiaries with CHD-related hospitalization, filled prescriptions for antihypertensive, initiation of statin therapy within 90 days of hospital discharge	1
Yang et al. (59)	Medicare Part D Enrollees	2005-2006	962,877	53.6%†	Medicare Part D enrollees with diabetes	0.5
Foody et al. (60)	PharmMetrics Patient Centric Database	2003-2005	11,331	50%§	Statin naïve adults with a prior cardiac event and ≥1 prescription for atorvastatin or simvastatin	0.75
Ye et al. (61)	MedStat MarketScan Commercial Claims and Encounters Database + Medicare Supplemental and Coordination of Benefit Database	2000-2002	5,548	61.4%	Patients who initiated statin treatment within 6 months of hospitalization for cardiovascular disease	1

"Interview with medication review. †Proportion of days covered ≥80%. ‡Proportion of days covered ≥50%. §Continuation without >60-day gap. ||Medication possession ratio ≥80%. Abbreviations as in Table 1.

Study (Ref. #)	Year	N	Statin Studied	Discontinuation of Statin Therapy	Follow-Up Duration	Average Annual % Discontinuation
IMPROVE-IT (6)	2014	18,144	Simvastatin	42%	72 months*	7.0%
SEARCH (52)	2010	12,064	Simvastatin	27%	80 months†	4.1%
IDEAL (53)	2005	8,888	Atorvastatin	14%	58 months*	2.9%
TNT (54)	2005	10,001	Atorvastatin	7%‡	59 months*	1%‡
A to Z (19)	2004	4,497	Simvastatin	34%	24 months*	17.2%
PROVE IT-TIMI 22 (14)	2004	4,162	Atorvastatin	30%	24 months†	15.2%
HPS (55)	2002	20,536	Simvastatin	18%	60 months†	3.6%
LIPID (56)	1998	9,014	Pravastatin	19%	73 months	3.1%
CARE (57)	1996	4,159	Pravastatin	6%	60 months*	1.2%
45 (58)	1994	4,444	Simvastatin	10%	65 months*	1.9%

*Median. †Mean. ‡Discontinuation due to treatment-related adverse events only. All-cause discontinuation was not reported.

45 = Scandinavian Simvastatin Survival Study; ACS = acute coronary syndrome(s); A to Z = Aggrastat to Zocor; CARE = Cholesterol and Recurrent Events; HPS = Heart Protection Study; IDEAL = Incremental Decrease in End Points Through Aggressive Lipid Lowering; IMPROVE-IT = IMProved Reduction of Outcomes: Vytorin Efficacy International Trial; LIPID = Long-Term Intervention with Pravastatin in Ischaemic Disease; PROVE IT-TIMI 22 = Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22; RCT = randomized controlled trial; SEARCH = Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine; TNT = Treating to New Targets.

(J Am Coll Cardiol 2015;66:184-92)



Figure 1 Study flow.

Abbreviations: BNK, Bundesverband Niedergelassener Kardiologen (German Federation of Office-Based Cardiologists); QoL, quality of life.


Vascular Health and Risk Management


Dovepress
open access to scientific and medical research

Open Access Full Text Article

ORIGINAL RESEARCH

High adherence to therapy and low cardiac mortality and morbidity in patients after acute coronary syndrome systematically managed by office-based cardiologists in Germany: I-year outcomes of the ProAcor Study





Vascular Health and Risk Management 2017:13 127-137

Vascular Health and Risk Management


Dovepress

Open Access Full Text Artic

ORIGINAL RESEARCH

High adherence to therapy and low cardiac mortality and morbidity in patients after acute coronary syndrome systematically managed by office-based cardiologists in Germany: I-year outcomes of the ProAcor Study

Vascular Health and Risk Management 2017:13 127-137





2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

prevention.^{14,21,22} Nevertheless, mortality remains substantial; the inhospital mortality of unselected patients with STEMI in the national registries of the ESC countries varies between 4 and 12%,²³ while reported 1-year mortality among STEMI patients in angiography registries is approximately 10%.^{24,25}

European Heart Journal (2018) **39**, 119–177 doi:10.1093/eurheartj/ehx393



ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

4.4.1 Lifestyle interventions and risk factor control

Key lifestyle interventions include cessation of smoking and tight blood pressure control, advice regarding diet and weight control, and the encouragement of physical activity. Detailed recommendations are available from the ESC guidelines on prevention. Even though long-term management of this large group of patients will be the responsibility of the primary care physician, these interventions will have a higher chance of being implemented if initiated during the hospital stay. In addition, the benefits and importance of lifestyle changes should be explained and proposed to the patient—who is the key player—before discharge. However, habits of a lifetime are not easily changed, and the implementation and follow-up of these changes are a long-term undertaking. In this regard, a close collaboration between the cardiologist and the general practitioner, specialist rehabilitation nurses, pharmacists, dieticians, physiotherapists is critically important.

Each hospital participating in the care of STEMI patients must have a smoking cassation protocol. Exercise-based rehabilitation is recommended. Arciplatelet therapy with low dose aspirin (75–100 mg) is indicated indefinitely after STEMI. In patients who are intolerant to aspirin, clopidogral is indicated as an alternative to aspirin. In patients who are intolerant to aspirin and prassignal or aspirin and straggralor is recommended (over aspirin and deployloging) in patients treated with PCI. DAPT with a combination of aspirin and prassignal or aspirin and straggralor is recommended (over aspirin and an oral ADP receptor antagonist must be continued for up to 12 months after STEMI, with a strict minimum of: In oral patients receiving BMS In patients with a clear indication for oral anticoagulation should be instituted for a minimum of 3 months. In patients with a clear indication for oral anticoagulation (a.g. atrial fibrillation with CHA_DS_VASc Score 20 or manchanical valve prorothesis), oral anticoagulation must be implemented in addition to antipatelet therapy. If patients with a clear indication for oral anticoagulation flowers and an oral ADP receptor of dela integration of the delay in the patients of the patients require triple antitrombotic therapy combining DAPT and OAC, e.g. because of stant placement and an obligatory indication for CAC, the duration of dela integralizated therapy should be minimized to reduce blaceding risk. In assistant patients who receive aspirin and clopidogral, low-dose rivarosaban (2.5 mg twice daily) may be considered life. B. C. adatric protection with a patients with STEMI who did not receive a stant. Castric protection with a patients with STEMI who did not receive a stant. Castric protection with a patient such as a post of the duration of DAPT therapy is patients at indicated in patients with heart failure or UV dysfunction. In A 28 Intravenous beta-blockers should be considered during hospital stay and continued thereafter in all STEMI patients at high bl	Recommendations	Class*	Level	Ref ^C
Exercise-based rehabilitation is recommended. Antiplatelet therapy with low dose appirin (75-100 mg) is indicated indefinitely after STEMI. In patients who are intolerant to aspirin, clopidogral is indicated as an alternative to aspirin. In patients who are intolerant to aspirin, clopidogral is indicated as an alternative to aspirin. In patients who are intolerant to aspirin, clopidogral is indicated as an alternative to aspirin. In DAPT with a combination of aspirin and prasugral or aspirin and disagnelor is recommended (over aspirin and clopidogral) in patients are alternated with PCI. DAPT with a spirin and an oral ADP receptor arizagonist must be continued for up to 12 months after STEMI, with a strict minimum of 3. I month for patients receiving BMS I most in the second of the secondary of the intolerance of the patients who receive a patient and clopidogral, low-dose rivarceaban (2.5 mg twice daily) may be considered in a selected patient in who receive a patient and intolerance of the patients with a proton pump inhibitor should be considered for the duration of DAPT therapy in patients at link phyrite of bleeding. DAPT should be used up to 1 year in patients with STEMI who did not receive a steric. In a selected patients with beat-blockers should be considered during hospital stay and continued thereafte	Active smokers with STEMI must receive counselling and be referred to a smoking cessation programme.	- 1	В	225
Anotherolect therapy with low dose appirin (75–100 mg) is indicated indefinitely after STEMI. In patients who are intolerant to aspirin, clopidogral is indicated as an alternative to aspirin. In patients who are intolerant to aspirin, clopidogral is indicated as an alternative to aspirin. In DAPT with a combination of appirin and prazugard or appirin and triaggalor is recommended (over appirin and clopidogral) in patients treated with PCI. In DAPT with appirin and an oral ADP receptor artagonist must be continued for up to 12 months after STEMI, with a sixtic minimum of the continued for up to 12 months after STEMI, with a sixtic minimum of the continued for up to 12 months after STEMI, with a sixtic minimum of the continued for up to 12 months after STEMI, with a sixtic minimum of the continued for up to 12 months after STEMI, with a sixtic minimum of the continued for a minimum of the continued to a continued the continued for a minimum of the continued to reduce blooding risk. In patients with a clear indication for oral articoagulation (e.g. atrial fibrillation with CHA, DS, VASc Score 22 or machanical valve prosthesists), oral anticoagulation must be implemented in a difficient to antiplated therapy. If patients require triple anotheromotor therapy, combining DAPT and CAPC, e.g. because of sent placement and an antiplated patients with a require antiplated therapy should be minimized to reduce blooding risk. In selected patients with or receive apprire and clopidogral, low-dose rivarovaban (2.5 mg twice daily) may be considered. In patients with or receive apprire and clopidogral, low-dose rivarovaban (2.5 mg twice daily) may be considered. In patients with or receive apprire and clopidogral, low-dose rivarovaban (2.5 mg twice daily) may be considered.	Each hospital participating in the care of STEMI patients must have a smoking cassation protocol.	1	С	-
In patients who are intolerant to aspirin, clopidogral is indicated as an alternative to aspirin. In patients who are intolerant to aspirin, clopidogral is indicated as an alternative to aspirin. In DAPT with a combination of aspirin and prassgral or aspirin and triagralor is recommended (over aspirin and clopidogral) in patients treated with PCI. DAPT with aspirin and an oral ADP receptor antagonist must be continued for up to 12 months after STEMI, with a strict minimum of 1 months for patients recalving BMS I C I month for patients recalving BMS I D DAPT with a clear indication for out anticoagulation should be instituted for a minimum of 3 months. III B B 34 In patients with at ventricular thrombus, anticoagulation (e.g. atrial fibrillation with CHA,DS,-VASc Score 22 or machanical valve prosthesis), oral anticoagulation must be implemented in addition to antiplateal therapy. If patients require triple antithrombotic therapy combining DAPT and OAC, e.g. because of stent placement and an obligatory indication for OAC, the duration of dual antiplatealet therapy should be minimated to reduce blooding risk. In selected patients who receive a aspirin and clopidogral, low-dose rivarousaban (2.5 mg twice duly) may be considered if the patient is at low blooding risk. DAPT should be used up to 1 year in patients with STEMI who did not receive a start. III C Gastric protection with a proton pump inhibitor should be considered for the duration of DAPT therapy in patients at high patients with buts-blockers should be considered during hospital stay and continued thereafter in all STEMI is a patients without contraindications. Oral treatment with beta-blockers is indicated in patients with heart failure or LV dysfunction. I A 29 Intravenous beta-blockers should be considered at the time of presentation in patients without contraindications, with high blood pressure, tachycards and no ages of heart failure. III B II	Exercise-based rehabilitation is recommended.	1	В	232,233
DAPT with a combination of aspirin and prassgral or aspirin and ticagralor is recommended (over aspirin and clopkdogrel) in patients treated with PCI. DAPT with sapirin and an oral ADP receptor antagonist must be continued for up to 12 months after STEMI, with a line of the continuance of the con	Antiplatelet therapy with low dose aspirin (75–100 mg) is indicated indefinitely after STEMI.	1	A	237
dopklogrel) in patients treated with PCL DAPT with applinn and an oral ADP receptor artagenist must be continued for up to 12 months after STEMI, with a strict minimum of: - I month for patients recalving BMS - 6 months for patients recalving BMS - 6 months for patients recalving BMS - 1 In patients with left westricular thrombus, articoagulation should be instituted for a minimum of 3 months. III B 3 H In patients with a clear indication for oral articoagulation (e.g. strial fibrillation with CHA,DS,VASC Score 22 or machanical valve prosthesis), oral anticoagulation must be implemented in addition to antipitatelet therapy. If patients require triple artithrombotic therapy, combining DAPT and OAC, e.g. because of stant placement and an obligatory indication for OAC, the duration of dual antipitatelet therapy should be minimized to reduce bleeding risk. In selected patients who receive applins and clopidogral, low-dose rivarceaban (2.5 mg twice daily) may be considered III B DAPT should be used up to 1 year in patients with STEMI who did not receive a start. III C Gastric protection with a proton pump inhibitor should be considered for the duration of DAPT therapy in patients at high risk of bleeding. Oral treatment with beta-blockers should be considered during hospital stay and continued thereafter in all STEMI patients without contraindications. III B III B III C Intravenous beta-blockers must be avoided in patients with high other stantage or LV dydinction. I A 28 Intravenous beta-blockers should be considered at the time of presentation in patients without contraindications, with high blood pressure, tachycarcha and no signs of heart failure. III B III C III C A fasting lipid profile must be obtained in all STEMI patients, as soon as possible after presentation. I C III C A Fasting lipid profile must be obtained in all STEMI patients, as soon as possible after presentation. II C III C A Fasting lipid profile must be obtained in all STEMI patients, as soon as possible after pre	In patients who are intolerant to aspirin, clopidogrel is indicated as an alternative to aspirin.	1	В	243
In month for patients recalving BMS • In month for patients recalving BMS • In month for patients recalving BMS • In patients with left ventricular thrombus, anticoagulation (e.g. atrial fibrillation with CHA,DS, VASc Score 22 or machanical valve prosthesis), oral anticoagulation (e.g. atrial fibrillation with CHA,DS, VASc Score 22 or machanical valve prosthesis), oral anticoagulation must be implemented in addition to antipitatelet therapy. If patients require triple antithrombotic therapy, combining DAPT and OAC, e.g. because of stent placament and an obligatory indication for OAC, the duration of dual antiplatelet therapy should be minimized to reduce bleeding risk. In salected patients who receive applies and clopidogral, low-dose rivarosaban (2.5 mg twice duly) may be considered in the patient is at low bleeding risk. DAPT should be used up to 1 year in patients with STEMI who did not receive a stant. DAPT about be used up to 1 year in patients with STEMI who did not receive a stant. III. C static protection with a proton pump inhibitor should be considered for the duration of DAPT therapy in patients at high risk of bleeding. Oral treatment with bata-blockers should be considered during hospital stay and continued thereafter in all STEMI patients without contraindications. Intravenous bata-blockers is indicated in patients with heart failure or LV dysfunction. I A 28 Intravenous bata-blockers must be avoided in patients with heart failure or LV dysfunction. III. B Intravenous bata-blockers should be considered at the time of presentation in patients without contraindications, with high blood pressure, tachycards and no legis of heart failure. A fasting lipid profile must be obtained in all STEMI patients, as soon as possible after presentation. I C III. A it is recommended to initiate or continue high dose statins early after admission in all STEMI patients without contraindications to beta-blockers and no heart failure. Varapamil may be considered for secondary prevention in patients w		1	A	109,110
In patients with a clear indication for oral anticoagulation should be instituted for a minimum of 3 months. In patients with last ventricular thrombus, anticoagulation should be instituted for a minimum of 3 months. In patients with a clear indication for oral anticoagulation must be implemented in addition to antipitatelet therapy. If patients require triple antithrombotic therapy, combining DAPT and CAC, e.g. because of storet placament and an obligatory indication for CAC, the duration of dual antiplatelet therapy should be minimized to reduce bleeding risk. In selected patients who receive aspirin and clopidogral, low-dose rivarosaban (2.5 mg twice daily) may be considered if the patient is at low bleeding risk. In selected patients who receive aspirin and clopidogral, low-dose rivarosaban (2.5 mg twice daily) may be considered if the patient is at low bleeding risk. In selected patients who receive aspirin and clopidogral, low-dose rivarosaban (2.5 mg twice daily) may be considered if the patient is at low bleeding risk. In selected patients who receive aspirin and clopidogral, low-dose rivarosaban (2.5 mg twice daily) may be considered III C Calculation protection with a protein pump inhibitor should be considered for the duration of DAPT therapy in patients at high risk of bleeding. Oral treatment with bata-blockers should be considered during hospital stay and continued thereafter in all STEMI lia. Intravenous bata-blockers is indicated in patients with heart failure or LV dysfunction. I A 28 Intravenous bata-blockers use the avoided in patients with heart failure or LV dysfunction. I A 28 It is recommended to initiate or continue high dose statins early after admission in patients without contraindications, with high blood pressure, tadycards and no legis of heart failure. A facting lipid profile must be obtained in all STEMI patients, as soon as possible after presentation. I C II A C III A		1	С	245-247
In patients with left ventricular thrombus, anticoagulation should be instituted for a minimum of 3 months. III a 3 44 In patients with a clear indication for oral anticoagulation (e.g. atrial fibrillation with CHA_DS_VASc Score 22 or machanical valve prosthesis), oral anticoagulation (e.g. atrial fibrillation with CHA_DS_VASc Score 22 or machanical valve prosthesis), oral anticoagulation must be implemented in addition to antiplateals therapy. If patients require triple antithromboot renapy combining DAPT and OAC, e.g. because of stont placement and an obligatory indication for OAC, the duration of dual antiplatealet therapy should be minimate to reduce belong risk. In selected patients who receive aspirin and clopidogral, low-dose rivaroxaban (2.5 mg twice daily) may be considered if the patients at low bleeding risk. DAPT should be used up to 1 year in patients with STEMI who did not receive a start. III a C Gastric protection with a proton pump inhibitor should be considered for the duration of DAPT therapy in patients at lia a C Gastric protection with a proton pump inhibitor should be considered for the duration of DAPT therapy in patients at lia a C Gastric protection with a proton pump inhibitor should be considered for the duration of DAPT therapy in patients at lia a C Gastric protection with beta-blockers should be considered during hospital stay and continued thereafter in all STEMI is a lia a C Intravanous beta-blockers should be considered at the time of presentation. I A 29 Intravanous beta-blockers should be considered at the time of presentation in patients without contraindications, with high blood pressure, tachycards and no ages of heart failure. It is recommended to initiate or continue high dose statins early after admission in all STEMI patients without contraindications or history of intolerance, regardless of initial cholesterol values. It is recommended to initiate or continue high dose statins early after admission in all STEMI patients without contraindications to beta-bloc	I month for patients receiving BMS	- 1	С	293
In patients with a clear indication for oral anticoagulation (e.g. atrial fibriliation with CHA_DS_VASc Score 22 or machanical valve prosthesis), oral anticoagulation must be implemented in addition to antiplatelet therapy. If patients require triple antithrombotic therapy, combining DAPT and OAC, e.g. because of stent placement and an obligatory indication for OAC, the duration of dual antiplatelet therapy should be minimzed to reduce bleeding risk. It is selected patients who receive aspirin and clopidogral, low-dose rivarrosaban (2.5 mg twice daily) may be considered if the patient is at low bleeding risk. DAPT should be used up to 1 year in patients with STEMI who did not receive a stent. Illa C Gastric protection with a proton pump inhibitor should be considered for the duration of DAPT therapy in patients at high risk of bleeding. Oral treatment with beta-blockers should be considered during hospital stay and continued thereafter in all STEMI is a limit of bleeding. Oral treatment with beta-blockers indicated in patients with heart failure or LV dysfunction. Intravenous beta-blockers indicated in patients with hypotension or heart failure. Intravenous beta-blockers should be considered at the time of presentation in patients without contraindications, with high blood pressure, tachycardha and no signs of heart failure. It is recommended to initiate or continue high dose statins early after admission in all STEMI patients without contraindications or history of intolerance, regardless of initial cholesterol values. It is recommended to initiate or continue high dose statins early after admission in all STEMI patients without contraindications or history of intolerance, regardless of initial cholesterol values. It is recommended to initiate or continue high dose statins early after admission in all STEMI patients without contraindications to beta-blockers and no heart failure. It is recommended to initiate or continue high dose statins early after admission in all STEMI patients without contrain	6 months for patients receiving DES	Ш	В	
## Additional to the protection with a proton pump inhibitor should be considered during hospital stay and continued therapty in patients at his bits. blockers should be considered during hospital stay and continued therapty in patients at his bits. blockers should be considered during hospital stay and continued therapty in patients at his bits. blockers should be considered during hospital stay and continued theraption in all STEMI bits. Contravance bats. blockers should be considered during hospital stay and continued therapter in all STEMI bits. Contravance bats. blockers should be considered during hospital stay and continued therapter in all STEMI bits. Contravance bats. blockers should be considered during hospital stay and continued therapter in all STEMI bits. Contravance bats. blockers is indicated in patients with heart failure or LV dysfunction. If a 29 lintravance bats. blockers should be considered during hospital stay and continued therapter in all STEMI bits. Bits	In patients with left ventricular thrombus, anticoagulation should be instituted for a minimum of 3 months.	lla	В	344-34
obligatory indication for OAC, the duration of dual antiplatelet therapy should be minimized to reduce bleeding risk. In selected patients who receive agains and clopidogral, low-dose rivarcacles (2.5 mg twice daily) may be considered IIIb B C DAPT should be used up to 1 year in patients with STEMI who did not receive a stant. Gastric protection with a proton pump inhibitor should be considered for the duration of DAPT therapy in patients at high risk of bleeding. Oral treatment with beta-blockers should be considered during hospital stay and continued thereafter in all STEMI B IIIa C Crail treatment with beta-blockers in indicated in patients with heart failure or LV dysfunction. I A 28 Intravenous beta-blockers must be avoided in patients with heart failure or LV dysfunction. III B III C III B III C III B III C III C III C A tasting lipid profile must be obtained in all STEMI patients, as soon as possible after presentation. III A fasting lipid profile must be obtained in all STEMI patients, as soon as possible after presentation. III C III A contravenous beta-blockers should be considered at the time of presentation in patients without contraindications, with high blood pressure, tactycarcha and no ages of heart failure. A fasting lipid profile must be obtained in all STEMI patients, as soon as possible after presentation. III C III A contraindication or history of intolarance, regardless of initial cholesterol values. Reassessment of LDL-cholesterol should be considered after 4-6 weeks to ensure that a target value of \$1.8 mmoll. IIIa C (III) C (III) A contraindication or history of intolarance, regardless of initial cholesterol values. Reassessment of LDL-cholesterol should be considered after 4-6 weeks to ensure that a target value of \$1.8 mmoll. III C ACE inhibitors are indicated starting within the first 24 h of STEMI in patients with evidence of heart failure, LV ACE inhibitors are indicated arting within the first 24 h of STEMI in patients with hea		1	С	
if the patient is at low bleeding risk. DAPT should be used up to 1 year in patients with STEMI who did not receive a start. III. Gastric protection with a proton pump inhibitor should be considered for the duration of DAPT therapy in patients at high risk of bleeding. Oral treatment with beta-blockers should be considered during hospital stay and continued thereafter in all STEMI patients without contraindications. Oral treatment with beta-blockers is indicated in patients with heart failure or LV dysfunction. I A 29 Intravanous beta-blockers must be avoided in patients with hypotension or heart failure. Intravanous beta-blockers should be considered at the time of presentation in patients without contraindications, with high blood pressure, tachycards and no signs of heart failure. III. A fasting lipid profile must be obtained in all STEMI patients, as soon as possible after presentation. It is recommended to initiate or continue high dose statins early after admission in all STEMI patients without contraindications or history of intolerance, regardless of initial cholesterol values. III. A contraindication or history of intolerance, regardless of initial cholesterol values. III. C (Ingrid) In seen reached. Varapemil may be considered for secondary prevention in patients with absolute contraindications to beta-blockers and no heart failure. ACE inhibitors are indicated starting within the first 24 h of STEMI in patients with evidence of heart failure, LV systolic dysfunction, diabetes or an antatrior infarct. An ARB preferably valaaran, is an alternative to ACE inhibitors in patients with heart failure or LV systolic dysfunction.		1	С	-
Gastric protection with a proton pump inhibitor should be considered for the duration of DAPT therapy in patients at high risk of bloeding. Oral treatment with beta-blockers should be considered during hospital stay and continued thereafter in all STEMI patients without contraindications. Intravenous beta-blockers is indicated in patients with heart failure or LV dysfunction. Intravenous beta-blockers should be considered at the time of presentation in patients without contraindications, with high blood pressure, tachycardia and no signs of heart failure. Intravenous beta-blockers should be considered at the time of presentation in patients without contraindications, with high blood pressure, tachycardia and no signs of heart failure. A fasting lipid profile must be obtained in all STEMI patients, as soon as possible after presentation. It is recommended to initiate or continue high dose statins early after admission in all STEMI patients without contraindication or history of intolerance, regardless of initial cholesterol values. Reassessment of LDL-cholesterol should be considered after 4-6 weeks to ensure that a target value of \$1.8 mmol/L. (70 mg/dL) has been reached. Varapemil may be considered for secondary prevention in patients with absolute contraindications to beta-blockers and no heart failure. ACE inhibitors are indicated starting within the first 24 h of STEMI in patients with evidence of heart failure, LV systolic dysfunction, diabetes or an antenior infarct. An ARB, preferably valartan, is an absurreative to ACE inhibitors in patients with heart failure or LV systolic dysfunction,		Шь	В	262
high risk of bloading. Oral treatment with beta-blockers should be considered during hospital stay and continued thereafter in all STEMI patients without contraindications. Oral treatment with beta-blockers is indicated in patients with heart failure or LV dysfunction. I A 28 Intravenous beta-blockers must be avoided in patients with hypotention or heart failure. Intravenous beta-blockers should be considered at the time of presentation in patients without contraindications, with high blood pressure, tachycardia and no signs of heart failure. A fasting lipid profile must be obtained in all STEMI patients, as soon as possible after presentation. I C It is recommended to initiate or continue high dose statins early after admission in all STEMI patients without contraindication or history of intolerance, regardless of initial cholesterol values. Reassessment of LDL-cholesterol should be considered after 4-6 weeks to ensure that a target value of ≤1.8 mmol/L. (70 mg/dL) has been reached. Varapemil may be considered for secondary prevention in patients with absolute contraindications to beta-blockers and no heart failure. ACE inhibitors are indicated starting within the first 24 h of STEMI in patients with evidence of heart failure, LV systolic dysfunction, diabetes or an antenior infarct. An ARB, preferably valartan, is an alternative to ACE inhibitors in patients with heart failure or LV systolic dysfunction,	DAPT should be used up to 1 year in patients with STEMI who did not receive a stant.	lla	С	-
patients without contraindications. Oral treatment with bata-blockers is indicated in patients with heart failure or LV dysfunction. I A 28 Intravanous bata-blockers should be considered at the time of presentation in patients without contraindications, with high blood pressure, tachycards and no signs of heart failure. Intravanous bata-blockers should be considered at the time of presentation in patients without contraindications, with high blood pressure, tachycards and no signs of heart failure. A fasting lipid profile must be obtained in all STEMI patients, as soon as possible after presentation. I C It is recommended to initiate or continue high dose statins early after admission in all STEMI patients without contraindication or history of intolerance, regardless of initial cholesterol values. Reassessment of LDL-cholesterol should be considered after 4-6 weeks to ensure that a target value of \$1.8 mmol/L. Varapemil may be considered for secondary prevention in patients with absolute contraindications to beta-blockers and no heart failure. ACE inhibitors are indicated starting within the first 24 h of STEMI in patients with evidence of heart failure, LV systolic dysfunction, diabetes or an anterior infarct. An ARB, preferably valarrant, is an alternative to ACE inhibitors in patients with heart failure or LV systolic dysfunction.		lla	С	256
Intravenous bata-blockers must be avoided in patients with hypotension or heart failure. Intravenous bata-blockers must be avoided in patients with hypotension or heart failure. Intravenous bata-blockers should be considered at the time of presentation in patients without contraindications, with high blood pressure, tachycardia and no signs of heart failure. A fasting lipid profile must be obtained in all STEMI patients, as soon as possible after presentation. It is recommended to initiate or continue high dose statins early after admission in all STEMI patients without contraindication or history of intoherance, regardless of initial cholesterol values. Reassessment of LDL-cholesterol should be considered after 4-6 weeks to ensure that a target value of \$1.8 mmol/L. (70 mg/dL) has been reached. Virapemil may be considered for secondary prevention in patients with absolute contraindications to beta-blockers and no heart failure. ACE inhibitors are indicated starting within the first 24 h of STEMI in patients with evidence of heart failure, LV systolic dysfunction, diabetes or an antenior infarct. An ARB, preferably valartan, is an alternative to ACE inhibitors in patients with heart failure or LV systolic dysfunction,		lla	В	1,266
Intravenous beta-blockers should be considered at the time of presentation in patients without contraindications, with high blood pressure, tachycardia and no signs of heart failure. A fasting lipid profile must be obtained in all STEMI patients, as soon as possible after presentation. It is recommended to initiate or continue high dose statine early after admission in all STEMI patients without contraindication or history of intolerance, regardless of initial cholesterol values. Reassessment of LDL-cholesterol should be considered after 4-6 weeks to ensure that a target value of \$1.8 mmol/L. (70 mg/dL) has been reached. Virapemil may be considered for secondary prevention in patients with absolute contraindications to beta-blockers and no heart failure. ACE inhibitors are indicated starting within the first 24 h of STEMI in patients with evidence of heart failure, LV systolic dysfunction, diabetes or an antenior infarct. An ARB, preferably valantan, is an alternative to ACE inhibitors in patients with heart failure or LV systolic dysfunction,	Oral treatment with beta-blockers is indicated in patients with heart failure or LV dysfunction.	1	A	294-28
high blood pressure, tachycardia and no signs of heart failure. A fasting lipid profile must be obtained in all STEMI patients, as soon as possible after presentation. It is recommended to initiate or continue lipid dose statine surfly after admission in all STEMI patients without contrahidication or history of intolerance, regardless of initial cholesterol values. It A Reassessment of LDL-cholesterol should be considered after 4-6 weeks to ensure that a target value of ≤1.8 mmol/L. (70 mg/dL) has been reached. Varapemil may be considered for secondary prevention in patients with absolute contraindications to beta-blockers and no heart failure. ACE inhibitors are indicated starting within the first 24 h of STEMI in patients with evidence of heart failure, LV systolic dysfunction, diabetes or an anterior infarct. An ARR, preferably valantan, is an alternative to ACE inhibitors in patients with heart failure or LV systolic dysfunction,	Intravenous beta-blockers must be avoided in patients with hypotension or heart failure.	Ш	В	266
It is recommended to initiate or continue high dose statins early after admission in all STEMI patients without It is recommended to initiate or continue high dose statins early after admission in all STEMI patients without Contraindication or history of intolerance, regardless of initial cholesterol values. Reassassment of LDL-cholesterol should be considered after 4-6 weeks to ensure that a target value of \$1.8 mmol/L III Cong/dl. has been reached. Varapemil may be considered for secondary prevention in patients with absolute contraindications to beta-blockers III ACE inhibitors are indicated starting within the first 24 h of STEMI in patients with evidence of heart failure, LV systolic dysfunction, diabetes or an antenior infarct. An ARR, preferably valantan, is an alternative to ACE inhibitors in patients with heart failure or LV systolic dysfunction,	Intravenous beta-blockers should be considered at the time of presentation in patients without contraindications, with high blood pressure, tachycardia and no signs of heart failure.	Ila	В	266
contraindication or history of intolerance, regardless of initial cholesterol values. Reassessment of LDL-cholesterol should be considered after 4-6 weeks to ensure that a target value of \$1.8 mmol/L (70 mg/dL) has been reached. Varapemil may be considered for secondary prevention in patients with absolute contraindications to beta-blockers and no heart failure. ACE inhibitors are indicated starting within the first 24 h of STEMI in patients with evidence of heart failure, LV systolic dysfunction, diabetes or an antentor infarct. An ARR, preferably valantan, is an alternative to ACE inhibitors in patients with heart failure or LV systolic dysfunction,	A fasting lipid profile must be obtained in all STEMI patients, as soon as possible after presentation.	1	С	-
(70 mg/dL) has been reached. Verapamil may be considered for secondary prevention in patients with absolute contraindications to beta-blockers IIIb B ACE inhibitors are indicated starting within the first 24 h of STEMI in patients with evidence of heart failure, LV systolic dysfunction, diabetes or an anterior infarct. An ARR, preferably valantan, is an alternative to ACE inhibitors in patients with heart failure or LV systolic dysfunction,		1	A	267
and no heart failure. ACE inhibitors are indicated starting within the first 24 h of STEMI in patients with evidence of heart failure, LV systolic dysfunction, diabetes or an anterior infarct. An ARR, preferably valuarizin, is an alternative to ACE inhibitors in patients with heart failure or LV systolic dysfunction,		lla	С	270
systolic dysfunction, diabetes or an anterior infarct. An ARR, preferably valuarizin, is an alternative to ACE inhibitors in patients with heart failure or LV systolic dysfunction,		IIb	В	276
		1	A	279
		1	В	280,28
ACE inhibitors should be considered in all patients in the absence of contraindications.	ACE inhibitors should be considered in all patients in the absence of contraindications.	lla	A	289, 290

Thirty Year Trends (1975-2005) in the Magnitude, Management, and Hospital Death Rates Associated With Cardiogenic Shock in Patients with Acute Myocardial Infarction: A Population-Based Perspective

Robert J. Goldberg, Ph.D. 1 , Frederick A. Spencer, M.D. 2 , Joel M. Gore, M.D. 1 , Darleen Lessard, M.S. 1 , and Jorge Yarzebski, M.D., M.P.H. 1

¹Department of Medicine, Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, MA 01655




Figure 1.
Trends in the Incidence Rates of Cardiogenic Shock in Patients With Acute Myocardia




Figure 2.

Trends in Hospital Case-Fatality Rates (CFR's) in Patients With Acute Myocardial Infarction
According to the Presence of Cardiogenic Shock

²Department of Medicine, McMaster University, Hamilton, Ontario Canada

The New England Journal of Medicine

© Copyright, 1999, by the Massachusetts Medical Society

VOLUME 341 AUGUST 26, 1999 NUMBER 9



EARLY REVASCULARIZATION IN ACUTE MYOCARDIAL INFARCTION COMPLICATED BY CARDIOGENIC SHOCK

JUDITH S. HOCHMAN, M.D., LYNN A. SLEEPER, Sc.D., JOHN G. WEBB, M.D., TIMOTHY A. SANBORN, M.D., HARVEY D. WHITE, D.SC., J. DAVID TALLEY, M.D., CHRISTOPHER E. BULLER, M.D., ALICE K. JACOBS, M.D., JAMES N. SLATER, M.D., JACQUES COL, M.D., SONJA M. McKINLAY, Ph.D., AND THIERRY H. LEJEMTEL, M.D., FOR THE SHOCK INVESTIGATORS*





Figure 1. Overall 30-Day Survival in the Study.

The 30-day survival rate was 53.3 percent for patients assigned to revascularization and 44.0 percent for those assigned to medical therapy.

This study was a randomized trial evaluating early revascularization therapy to reduce the high mortality rate associated with cardiogenic shock complicating acute myocardial infarction. The primary end point, overall mortality at 30 days, was not significantly reduced by early revascularization. However, a benefit in terms of mortality was apparent six months after infarction.

Trends in Management and Outcomes of Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock

Figure 2. Revascularization Rates in Patients With Cardiogenic Shock at Presentation (n=7356)



Data are through May 2004. P values indicate trends over time: total percutaneous coronary intervention (PCI), P<.001; primary PCI, P<.001; total coronary artery bypass graft (CABG) surgery, P<.001; and immediate CABG surgery, P = .88.

Table 2. In-Hospital Mortality Rates*


No. (%) of Patients in NRMI Registry Presenting With Cardiogenic Shock Who Died

	Total	<75 y	≥75 y
1995	434 (60.3)	274 (55.8)	160 (69.9)
1996	510 (59.8)	290 (51.4)	220 (76.1)
1997	530 (60.7)	313 (53.3)	217 (75.9)
1998	413 (58.0)	225 (49.2)	188 (73.7)
1999	554 (55.9)	324 (50.3)	230 (66.3)
2000	475 (56.6)	258 (47.9)	217 (72.1)
2001	416 (52.1)	222 (43.9)	194 (66.4)
2002	339 (49.8)	187 (40.8)	152 (68.5)
2003	282 (51.3)	162 (44.7)	120 (63.8)
2004†	163 (47.9)	88 (39.5)	75 (64.1)
P value	<.001	<.001	<.001

Abbreviation: NRMI, National Registry of Myocardial Infarction.

^{*}The Mantel-Haenszel χ^2 probability for the 2-sided alternative hypothesis that a linear association exists is presented.

[†]Through May.



The NEW ENGLAND JOURNAL of MEDICINE


ESTABLISHED IN 1812


DECEMBER 21, 2017

VOL. 377 NO. 25

PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock

H. Thiele, I. Akin, M. Sandri, G. Fuernau, S. de Waha, R. Meyer-Saraei, P. Nordbeck, T. Geisler, U. Landmesser, C. Skurk, A. Fach, H. Lapp, J.J. Piek, M. Noc, T. Goslar, S.B. Felix, L.S. Maier, J. Stepinska, K. Oldroyd, P. Serpytis, G. Montalescot, O. Barthelemy, K. Huber, S. Windecker, S. Savonitto, P. Torremante, C. Vrints, S. Schneider, S. Desch, and U. Zeymer, for the CULPRIT-SHOCK Investigators*





The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

OCTOBER 4, 2012

VOL. 367 NO. 14

Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock

Holger Thiele, M.D., Uwe Zeymer, M.D., Franz-Josef Neumann, M.D., Miroslaw Ferenc, M.D., Hans-Georg Olbrich, M.D., Jörg Hausleiter, M.D., Gert Richardt, M.D., Marcus Hennersdorf, M.D., Klaus Empen, M.D., Georg Fuernau, M.D., Steffen Desch, M.D., Ingo Eitel, M.D., Rainer Hambrecht, M.D., Jörg Fuhrmann, M.D., Michael Böhm, M.D., Henning Ebelt, M.D., Steffen Schneider, Ph.D., Gerhard Schuler, M.D., and Karl Werdan, M.D., for the IABP-SHOCK II Trial Investigators*




Figure 1. Time-to-Event Curves for the Primary End Point.

Time-to-event curves are shown through 30 days after randomization for the primary end point of all-cause mortality. Event rates represent Kaplan–Meier estimates.

Inotropic/vasopressor agents may be con- sidered for haemodynamic stabilization.	ШЬ	U
Short-term mechanical support ^c may be considered in patients in refractory shock.	ШЬ	n
Routine intra-aortic balloon pumping is not indicated.	ш	В


CARG = common artery hunger graft summer FCLS = extracorporal life sum-

Effect of Early Initiation of Mechanical Circulatory Support on Survival in Cardiogenic Shock


CrossMark


Mir B. Basir, DO^a, Theodore L. Schreiber, MD^b, Cindy L. Grines, MD^b, Simon R. Dixon, MD^c, Jeffrey W. Moses, MD^d, Brijeshwar S. Maini, MD^e, Akshay K. Khandelwal, MD^a, E. Magnus Ohman, MD^f, and William W. O'Neill, MD^{a,*}

The role and timing of percutaneous mechanical circulatory support (MCS) devices in the treatment of acute myocardial infarction complicated by cardiogenic shock (AMICS) are not well understood. We sought to evaluate patient characteristics and predictors of outcomes in patients presenting with AMICS supported with an axial flow percutaneous MCS device; 287 consecutive unselected patients enrolled in the catheter-based ventricular assist device registry presenting with AMICS who underwent percutaneous coronary intervention (PCI) were included in this analysis. All patients were supported with either the Impella 2.5 or Impella CP. Mean patient age was 66 ± 12.5 years, 76% were men, and mean left ventricular ejection fraction was 25 ± 12%. Before receiving MCS, 80% of patients required inotropes or vasopressors and 40% were supported with intra-aortic balloon pump; 9% of patients were under active cardiopulmonary resuscitation at the time of MCS implantation. Survival to discharge was 44%. In a multivariate analysis, early implantation of a MCS device before PCI (p = 0.04) and before requiring inotropes and vasopressors (p = 0.05) was associated with increased survival. Survival was 66% when MCS was initiated 1.25 hours from shock onset, 37% when initiated within 1.25 to 4.25 hours, and 26% when initiated after 4.25 hours (p = 0.017). Survival was 68%, 46%, 35%, 35%, and 26% for patients requiring 0, 1, 2, 3, and ≥ 4 inotropes before MCS support, respectively (p < 0.001). In conclusion, MCS implantation early after shock onset, before initiation of inotropes or vasopressors and before PCI, is independently associated with improved survival in patients presenting with AMICS. © 2016 Elsevier Inc. All rights reserved. (Am J Cardiol nplantation. 2017;119:845-851)




igure 3. Inhospital survival rates as a function of shock onset to MCS nplantation.






Feasibility of early mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock: The Detroit cardiogenic shock initiative



Conclusion: Centers who adopted a regional shock protocol emphasizing the delivery of early MCS with invasive hemodynamic monitoring can achieve rapid door to support times and can improve survival in patients who present with AMICS. Larger national studies will be needed to further validate this pilot feasibility study.



1. Abiomed Impella Quality (IQ) Database , Jan 2015 to July 2016 for Aggregate DTW Metro Hospitals, all-comers who presented with AMICS, Survival to Explant


Cardiac Power Output Pre and Post MCS

Mechanical circulatory support in patients with cardiogenic shock in intensive care units: A position paper of the "Unité de Soins Intensifs de Cardiologie" group of the French Society of Cardiology, endorsed by the "Groupe Athérome et Cardiologie Interventionnelle" of the French Society of Cardiology

Laurent Bonello^{a,b,*}, Clement Delmas^{c,d}, Guillaume Schurtz^{e,f}, Guillaume Leurent^g, Eric Bonnefoy^h, Nadia Aissaouiⁱ, Patrick Henry^j

CS in the context of ACS

In this situation, MCS should be considered early before PCI in the catheterization laboratory, to provide support and enable a safe revascularization procedure (Fig. 2).




Lo STEMI: uno stallone domato ? In parte si, tuttavia...

...per un'ulteriore riduzione della mortalità i campi di azione e miglioramento sono :

- 1. la fase post-acuta
- 2. lo shock cardiogeno





Interventi in Azienda

- 1. Shock Team multidisciplinare
- 2. Impiego di device di assistenza ventricolare (Impella ed ECMO)
- 3. Incontri di educazione sanitaria (Team Multidisciplinare con cardiologo, infermiere della cardiologia, dietista, personale del SERT, psicologo)
- 4. Estensione del FU della cardiopatia ischemica a 6 e 12 mesi



